A Phase 1 interventional study of T0001,10mg and T0001,20mg in Rheumatic Diseases, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-09.
Sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
The purpose of this study to assess the MTD and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers.
377 studies on the registry are indexed under Rheumatic Diseases; 79 are open to participants now.
This study's enrollment of 56 is below the median of 74 across 210 interventional studies indexed under Rheumatic Diseases.
Browse Rheumatic Diseases studies →Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is the lead sponsor of 24 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: T0001,10mg · Drug: T0001,20mg · Drug: T0001,35mg · Drug: T0001,50mg · Drug: T0001,65mg · Drug: T0001,75mg
Maximum Tolerance Dose
Time frame: 3 weeks
Adverse events
Time frame: 3 weeks
pharmacokinetics parameter(Cmax, AUC, t1/2, CL, etc)
Time frame: Pre-dose,2、4、12、24、36、48、60、72、84、96、120、144、168、216、264、312、384 and 480hours after the start of subcutaneous injection
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.